Bask­ing in lime­light of a CRISPR break­through, In­tel­lia bags $600M cash raise as shares soar to all-time high

“Raise mon­ey when you can, not when you have to” has be­come a fa­mil­iar re­frain in the biotech world. On the heels of a land­mark break­through for in vi­vo CRISPR/Cas9 edit­ing, In­tel­lia Ther­a­peu­tics is cer­tain­ly tak­ing it to heart.

The gene edit­ing pi­o­neer has loaded up in a new pub­lic of­fer­ing that sold its shares at $145 a pop — a 60% jump from its clos­ing price on Fri­day, just ahead of an in­dus­try-shak­ing mile­stone. Over the week­end, it dropped ini­tial da­ta sug­gest­ing that it can use CRISPR to di­rect­ly ed­it DNA in hu­mans, of­fer­ing a land­mark proof-of-con­cept for the bur­geon­ing field.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER